Biomarkers for basal-like breast cancer

Cancers

Volumn 2, Issue 2, 2010, Pages 1040-1065

  Choo, Jennifer R ^a   Nielsen, Torsten O ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Basal like; Basaloid; Biomarkers; Breast cancer; Expression profile; Immunohistochemistry; Intrinsic subtype; Triple negative

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CAVEOLIN 1; CAVEOLIN 2; CLAUDIN; CYCLOPHOSPHAMIDE; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KALININ; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OSTEONECTIN; OSTEOPONTIN; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CELL CYCLE REGULATION; DNA REPAIR; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROGNOSIS; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE;

EID: 79952263940     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2021040     Document Type: Review

References (180)

1. Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A. et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747-752.
2. Sorlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869-10874.
3. van't Veer, L.J.; Paik, S.; Hayes, D.F. Gene Expression Profiling of Breast Cancer: A New Tumor Marker. J. Clin. Oncol. 2005, 23, 1631-1635.
4. Matos, I.; Dufloth, R.; Alvarenga, M.; Zeferino, L.; Schmitt, F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005, 447, 688-694.
5. Nielsen, T.O.; Hsu, F.D.; Jensen, K.; Cheang, M.; Karaca, G.; Hu, Z.; Hernandez-Boussard, T.; Livasy, C.; Cowan, D.; Dressler, L.; et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. Clin. Cancer Res. 2004, 10, 5367-5374.
6. van de Rijn, M.; Perou, C.M.; Tibshirani, R.; Haas, P.; Kallioniemi, O.; Kononen, J.; Torhorst, J.; Sauter, G.; Zuber, M.; Kochli, O.R.; et al. Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome. Am. J. Pathol. 2002, 161, 1991-1996.
7. Bertucci, F.; Finetti, P.; Cervera, N.; Charafe-Jauffret, E.; Buttarelli, M.; Jacquemier, J.; Chaffanet, M.; Maraninchi, D.; Viens, P.; Birnbaum, D. How different are luminal A and basal breast cancers? Int. J. Cancer 2009, 124, 1338-1348.
8. Linn, S.C.; van't Veer, L.J. Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept. Eur. J. Cancer 2009, 45, 11-26.
9. Rakha, E.; El-Sayed, M.; Reis-Filho, J.; Ellis, I. Patho-biological aspects of basal-like breast cancer. Breast Cancer Res. Treat. 2009, 113, 411-422.
10. Zhang, H.; Rakha, E.; Ball, G.; Spiteri, I.; Aleskandarany, M.; Paish, E.; Powe, D.; Macmillan, R.; Caldas, C.; Ellis, I.; et al. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res. Treat. 2009, 121, 41-51.
11. Carey, L.A.; Perou, C.M.; Livasy, C.A.; Dressler, L.G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M.A.; Tse, C.K.; Edmiston, S.; et al. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. J Am. Med. Assoc. 2006, 295, 2492-2502.
12. Cheang, M.C.U.; Voduc, D.; Bajdik, C.; Leung, S.; McKinney, S.; Chia, S.K.; Perou, C.M.; Nielsen, T.O. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype. Clin. Cancer Res. 2008, 14, 1368-1376.
13. El-Rehim, D.M.A.; Pinder, S.E.; Paish, C.E.; Bell, J.; Blamey, R.W.; Robertson, J.F.R.; Nicholson, R.I.; Ellis, I.O. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004, 203, 661-671.
14. Reis-Filho, J.S.; Milanezi, F.; Steele, D.; Savage, K.; Simpson, P.T.; Nesland, J.M.; Pereira, E.M.; Lakhani, S.R.; Schmitt, F.C. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006, 49, 10-21.
15. Lae, M.; Freneaux, P.; Sastre-Garau, X.; Chouchane, O.; Sigal-Zafrani, B.; Vincent-Salomon, A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod. Pathol. 2008, 22, 291-298.
16. Bertucci, F.; Finetti, P.; Cervera, N.; Charafe-Jauffret, E.; Mamessier, E.; Adelaide, J.; Debono, S.; Houvenaeghel, G.; Maraninchi, D.; Viens, P.; et al. Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers. Cancer Res. 2006, 66, 4636-4644.
17. Azoulay, S.; Lae, M.; Freneaux, P.; Merle, S.; Al Ghuzlan, A.; Chnecker, C.; Rosty, C.; Klijanienko, J.; Sigal-Zafrani, B.; Salmon, R.; et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod. Pathol. 2005, 18, 1623-1631.
18. Weigelt, B.; Mackay, A.; A'Hern, R.; Natrajan, R.; Tan, D.S.P.; Dowsett, M.; Ashworth, A.; Reis-Filho, J.S. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010, 11, 339-349.
19. Sorlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J.S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. 2003, 100, 8418-8423.
20. Stingl, J.; Caldas, C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat. Rev. Cancer 2007, 7, 791-799.
21. Lim, E.; Vaillant, F.; Wu, D.; Forrest, N.C.; Pal, B.; Hart, A.H.; Asselin-Labat, M.-L.; Gyorki, D.E.; Ward, T.; Partanen, A.; et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009, 15, 907-913.
22. Bocker, W.; Moll, R.; Poremba, C.; Holland, R.; van Diest, P.J.; Dervan, P.; Burger, H.; Wai, D.; Ina Diallo, R.; Brandt, B.; et al. Common Adult Stem Cells in the Human Breast Give Rise to Glandular and Myoepithelial Cell Lineages: A New Cell Biological Concept. Lab. Invest. 2002, 82, 737-746.
23. Gusterson, B. Do 'basal-like' breast cancers really exist? Nat. Rev. Cancer. 2009, 9, 128-134.
24. Gusterson, B.; Ross, D.; Heath, V.; Stein, T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005, 7, 143-148.
25. Ramachandran, N.; Srivastava, S.; LaBaer, J. Applications of protein microarrays for biomarker discovery. Proteomics 2008, 2, 1444-1459.
26. Fadare, O.; Tavassoli, F.A. Clinical and pathologic aspects of basal-like breast cancers. Nat. Clin. Prac. Oncol. 2008, 5, 149-159.
27. Ross, J.S.; Linette, G.P.; Stec, J.; Clark, E.; Ayers, M.; Leschly, N.; Symmans, W.F.; Hortobagyi, G.N.; Pusztai, L. Breast cancer biomarkers and molecular medicine: part II. Expert Rev. Mol. Diagn. 2004, 4, 169-188.
28. Tainsky, M.A. Genomic and proteomic biomarkers for cancer: A multitude of opportunities. Biochim. Biophys. Acta Rev. Cancer 2009, 1796, 176-193.
29. Ward, T.H.; Cummings, J.; Dean, E.; Greystoke, A.; Hou, J.M.; Backen, A.; Ranson, M.; Dive, C. Biomarkers of apoptosis. Br. J. Cancer 2008, 99, 841-846.
30. Mohammadizadeh, F.; Naimi, A.; Rajabi, P.; Ghasemibasir, H.; Eftekhari, A. Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables. Indian J. Med. Sci. 2009, 63, 152-162.
31. Camp, R.L.; Neumeister, V.; Rimm, D.L. A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers. J. Clin. Oncol. 2008, 26, 5630-5637.
32. Tang, P.; Skinner, K.A.; Hicks, D.G. Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis: Are We Ready? Diagn. Mol. Pathol. 2009, 18, 125-132.
33. Simon, R. Advances in clinical trial designs for predictive biomarker discovery and validation. Curr. Breast Cancer Rep. 2009, 1, 216-221.
34. Simon, R.M.; Paik, S.; Hayes, D.F. Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. J. Natl. Cancer Inst. 2009, djp335.
35. Nielsen, T.O.; Jewell, S.D.; Thor, A.D.; Gao, D.; Perou, C.M.; Broadwater, G.; Harris, L.N.; Hayes, D.F.; Berry, D.A.; Ellis, M.J. Intrinsic subtype and response to paclitaxel in CALGB 9344 tissue microarrays. Presented at the ASCO 2009 Breast Cancer Symposium, San Francisco, CA, USA, October 2009.
36. Bertucci, F.; Finetti, P.; Cervera, N.; Esterni, B.; Hermitte, F.; Viens, P.; Birnbaum, D. How basal are triple-negative breast cancers? Int. J. Cancer 2008, 123, 236-240.
37. Wang, X.; Chao, L.; Ma, G.; Chen, L.; Tian, B.; Zang, Y.; Sun, J. Increased expression of osteopontin in patients with triple-negative breast cancer. Eur. J. Clin. Invest. 2008, 38, 438-446.
38. Kim, J.M.; Hwang, T.Y.; Kang, S.H.; Lee, S.J.; Bae, Y.K. Prognostic Significance of Basal Markers in Triple-negative Breast Cancers. J. Breast Cancer 2009, 12, 4-13.
39. Martín, M.; Rodríguez-Lescure, Á.; Ruiz, A.; Alba, E.; Calvo, L.; Ruiz-Borrego, M.; Santaballa, A.; Rodríguez, C.; Crespo, C.; Abad, M.; et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res. Treat. 2009, [Epub ahead of print].
40. Tan, E.Y.; Yan, M.; Campo, L.; Han, C.; Takano, E.; Turley, H.; Candiloro, I.; Pezzella, F.; Gatter, K.C.; Millar, E.K.A.; et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br. J. Cancer 2009, 100, 405-411.
41. Cheang, M.; Chia, S.K.; Tu, D.; Jiang, S.; Shepherd, L.E.; Pritchard, K.I.; Nielsen, T.O. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. Presented at the 2009 ASCO Annual Meeting, Orlando, FL, USA, May 2009.
42. Voduc, D.; Nielsen, T. Basal and Triple-Negative Breast Cancers: Impact on Clinical Decision-Making and Novel Therapeutic Options. Clin. Breast Cancer 2008, 8, s171-s178.
43. Rakha, E.A.; Elsheikh, S.E.; Aleskandarany, M.A.; Habashi, H.O.; Green, A.R.; Powe, D.G.; El-Sayed, M.E.; Benhasouna, A.; Brunet, J.S.; Akslen, L.A.; et al. Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes. Clin. Cancer Res. 2009, 15, 2302-2310.
44. Laakso, M.; Loman, N.; Borg, A.; Isola, J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod. Pathol. 2005, 18, 1321-1328.
45. Potemski, P.; Kusinska, R.; Watala, C.; Pluciennik, E.; Bednarek, A.K.; Kordek, R. Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer. Oncology 2005, 69, 478-485.
46. Rakha, E.A.; El-Sayed, M.E.; Green, A.R.; Paish, E.C.; Lee, A.H.S.; Ellis, I.O. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007, 50, 434-438.
47. Malzahn, K.; Mitze, M.; Thoenes, M.; Moll, R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998, 433, 119-129.
48. Dairkee, S.H.; Puett, L.; Hackett, A.J. Expression of Basal and Luminal Epithelium-Specific Keratins in Normal, Benign, and Malignant Breast Tissue1. J. Natl. Cancer Inst. 1988, 80, 691-695.
49. Wetzels, R.H.; Kuijpers, H.J.; Lane, E.B.; Leigh, I.M.; Troyanovsky, S.M.; Holland, R.; van Haelst, U.J.; Ramaekers, F.C. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am. J. Pathol. 1991, 138, 751-763.
50. Wetzels, R.H.; Holland, R.; van Haelst, U.J.; Lane, E.B.; Leigh, I.M.; Ramaekers, F.C. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am. J. Pathol. 1989, 134, 571-579.
51. Chen, P.C.; Chen, C.K.; Nicastri, A.D.; Wait, R.B. Myoepithelial carcinoma of the breast with distant metastasis and accompanied by adenomyoepitheliomas. Histopathology 1994, 24, 543-548.
52. Livasy, C.A.; Karaca, G.; Nanda, R.; Tretiakova, M.S.; Olopade, O.I.; Moore, D.T.; Perou, C.M. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2005, 19, 264-271.
53. Thike, A.A.; Cheok, P.Y.; Jara-Lazaro, A.R.; Tan, B.; Tan, P.; Tan, P.H. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod. Pathol. 2009, 23, 123-133.
54. Parker, J.S.; Mullins, M.; Cheang, M.C.U.; Leung, S.; Voduc, D.; Vickery, T.; Davies, S.; Fauron, C.; He, X.; Hu, Z.; et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J. Clin. Oncol. 2009, 27, 1160-1167.
55. Liu, Z.B.; Wu, J.; Ping, B.; Feng, L.Q.; Lu, J.S.; Shen, K.W.; Shen, Z.Z.; Shaol, Z.M. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple-negative phenotype. Tumori 2009, 95, 53-62.
56. Chen, M.H.S.; Wai-Cheong Yip, G.; Tse, G.M.-K.; Moriya, T.; Lui, P.C.-W.; Zin, M.-L.; Bay, B.-H.; Tan, P.-H. Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters. Mod. Pathol. 2008, 21, 1183-1191.
57. Rodriguez-Pinilla, S.M.; Sarrio, D.; Honrado, E.; Moreno-Bueno, G.; Hardisson, D.; Calero, F.; Benitez, J.; Palacios, J. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J. Clin. Pathol. 2007, 60, 1006-1012.
58. Sarrio, D.; Rodriguez-Pinilla, S.M.; Hardisson, D.; Cano, A.; Moreno-Bueno, G.; Palacios, J. Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. Cancer Res. 2008, 68, 989-997.
59. Rodriguez-Pinilla, S.M.; Sarrio, D.; Honrado, E.; Hardisson, D.; Calero, F.; Benitez, J.; Palacios, J. Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas. Clin. Cancer Res. 2006, 12, 1533-1539.
60. Yoder, B.J.; Tso, E.; Skacel, M.; Pettay, J.; Tarr, S.; Budd, T.; Tubbs, R.R.; Adams, J.C.; Hicks, D.G. The Expression of Fascin, an Actin-Bundling Motility Protein, Correlates with Hormone Receptor-Negative Breast Cancer and a More Aggressive Clinical Course. Clin. Cancer Res. 2005, 11, 186-192.
61. Caigang, L.; Bo, C.; Jun, Z.; Ruishan, Z.; Fan, Y.; Feng, J.; Huimian, X.; Ping, L. Clinical implications for nestin protein expression in breast cancer. Cancer Sci. 2009, 101, 815-819.
62. Li, H.; Cherukuri, P.; Li, N.; Cowling, V.; Spinella, M.; Cole, M.; Godwin, A.K.; Wells, W.; DiRenzo, J. Nestin Is Expressed in the Basal/Myoepithelial Layer of the Mammary Gland and Is a Selective Marker of Basal Epithelial Breast Tumors. Cancer Res. 2007, 67, 501-510.
63. Parry, S.; Savage, K.; Marchio, C.; Reis-Filho, J.S. Nestin is expressed in basal-like and triple negative breast cancers. J. Clin. Pathol. 2008, 61, 1045-1050.
64. Charafe-Jauffret, E.; Ginestier, C.; Monville, F.; Finetti, P.; Adelaide, J.; Cervera, N.; Fekairi, S.; Xerri, L.; Jacquemier, J.; Birnbaum, D.; et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2005, 25, 2273-2284.
65. Charafe-Jauffret, E.; Monville, F.; Bertucci, F.; Esterni, B.; Ginestier, C.; Finetti, P.; Cervera, N.; Geneix, J.; Hassanein, M.; Rabayrol, L.; et al. Moesin expression is a marker of basal breast carcinomas. Int. J. Cancer 2007, 121, 1779-1785.
66. Kusinska, R.; Kordek, R.; Pluciennik, E.; Bednarek, A.; Piekarski, J.; Potemski, P. Does vimentin help to delineate the so-called 'basal type breast cancer'? J. Exp. Clin. Cancer Res. 2009, 28, 118-126.
67. Ouban, A.; Ahmed, A.A. Claudins in human cancer: A review. Histol. Histopathol. 2010, 25, 83-90.
68. Blanchard, A.; Skliris, G.; Watson, P.; Murphy, L.; Penner, C.; Tomes, L.; Young, T.; Leygue, E.; Myal, Y. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch. 2009, 454, 647-656.
69. Kulka, J.; Szász, A.; Németh, Z.; Madaras, L.; Schaff, Z.; Molnár, I.; Tokés, A.-M. Expression of Tight Junction Protein Claudin-4 in Basal-Like Breast Carcinomas. Pathol. Oncol. Res. 2009, 15, 59-64.
70. Lanigan, F.; McKiernan, E.; Brennan, D.J.; Hegarty, S.; Millikan, R.C.; McBryan, J.; Jirstrom, K.; Landberg, G.; Martin, F.; Duffy, M.J.; et al. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int. J. Cancer 2009, 124, 2088-2097.
71. Elsheikh, S.E.; Green, A.R.; Rakha, E.A.; Samaka, R.M.; Ammar, A.A.; Powe, D.; Reis-Filho, J.S.; Ellis, I.O. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br. J. Cancer 2008, 99, 327-334.
72. Pinilla, S.; Honrado, E.; Hardisson, D.; Benítez, J.; Palacios, J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res. Treat. 2006, 99, 85-90.
73. Savage, K.; Lambros, M.B.K.; Robertson, D.; Jones, R.L.; Jones, C.; Mackay, A.; James, M.; Hornick, J.L.; Pereira, E.M.; Milanezi, F.; et al. Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis. Clin. Cancer Res. 2007, 13, 90-101.
74. Savage, K.; Leung, S.; Todd, S.; Brown, L.; Jones, R.; Robertson, D.; James, M.; Parry, S.; Rodrigues-Pinilla, S.; Huntsman, D.; et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res. Treat. 2008, 110, 245-256.
75. Sloan, E.K.; Ciocca, D.R.; Pouliot, N.; Natoli, A.; Restall, C.; Henderson, M.A.; Fanelli, M.A.; Cuello-Carrion, F.D.; Gago, F.E.; Anderson, R.L. Stromal Cell Expression of Caveolin-1 Predicts Outcome in Breast Cancer. Am. J. Pathol. 2009, 174, 2035-2043.
76. Witkiewicz, A.K.; Dasgupta, A.; Sammons, S.; Er, O.; Potoczek, M.B.; Guiles, F.; Sotgia, F.; Brody, J.R.; Mitchell, E.P.; Lisanti, M.P. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol. Ther. 2010, 2, Epub ahead of print.
77. Humphries, M.J.; Reynolds, A. Cell-to-cell contact and extracellular matrix. Curr. Opin. Cell Biol. 2009, 21, 613-615.
78. Helleman, J.; Jansen, M.P.H.M.; Ruigrok-Ritstier, K.; van Staveren, I.L.; Look, M.P.; Meijer-van Gelder, M.E.; Sieuwerts, A.M.; Klijn, J.G.M.; Sleijfer, S.; Foekens, J.A.; et al. Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response. Clin. Cancer Res. 2008, 14, 5555-5564.
79. Lakhani, S.R.; Reis-Filho, J.S.; Fulford, L.; Penault-Llorca, F.; van der Vijver, M.; Parry, S.; Bishop, T.; Benitez, J.; Rivas, C.; Bignon, Y.-J.; et al. Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. Clin. Cancer Res. 2005, 11, 5175-5180.
80. Jones, C.; Mackay, A.; Grigoriadis, A.; Cossu, A.; Reis-Filho, J.S.; Fulford, L.; Dexter, T.; Davies, S.; Bulmer, K.; Ford, E.; et al. Expression Profiling of Purified Normal Human Luminal and Myoepithelial Breast Cells: Identification of Novel Prognostic Markers for Breast Cancer. Cancer Res. 2004, 64, 3037-3045.
81. Rodrigues, L.R.; Lopes, N.; Sousa, B.; Vieira, D.; Milanezi, F.; Paulsson, M.; Lindmark-Mansson, H.; Teixeira, J.A.; Schmitt, F. Significance of osteopontin expression in human invasive breast tumour stroma. Open Breast Cancer J. 2009, 1, 1-9.
82. Wai, P.; Kuo, P. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008, 27, 103-118.
83. Carpenter, P.M.; Dao, A.V.; Arain, Z.S.; Chang, M.K.; Nguyen, H.P.; Arain, S.; Wang-Rodriguez, J.; Kwon, S.-Y.; Wilczynski, S.P. Motility Induction in Breast Carcinoma by Mammary Epithelial Laminin 332 (Laminin 5). Mol. Cancer Res. 2009, 7, 462-475.
84. Marinkovich, M.P. Laminin 332 in squamous-cell carcinoma. Nat. Rev. Cancer 2007, 7, 370-380.
85. Gilcrease, M.; Zhou, X.; Lu, X.; Woodward, W.; Hall, B.; Morrissey, P. Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. J. Exp. Clin. Cancer Res. 2009, 28, 67.
86. Lu, S.; Simin, K.; Khan, A.; Mercurio, A.M. Analysis of Integrin Beta4 Expression in Human Breast Cancer: Association with Basal-like Tumors and Prognostic Significance. Clin. Cancer Res. 2008, 14, 1050-1058.
87. Reis-Filho, J.S.; Steele, D.; Di Palma, S.; Jones, R.L.; Savage, K.; James, M.; Milanezi, F.; Schmitt, F.C.; Ashworth, A. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod. Pathol. 2006, 19, 307-319.
88. Hasegawa, M.; Moritani, S.; Murakumo, Y.; Sato, T.; Hagiwara, S.; Suzuki, C.; Mii, S.; Jijiwa, M.; Enomoto, A.; Asai, N.; et al. CD109 expression in basal-like breast carcinoma. Pathol. Int. 2008, 58, 288-294.
89. Arnes, J.B.; Brunet, J.-S.; Stefansson, I.; Begin, L.R.; Wong, N.; Chappuis, P.O.; Akslen, L.A.; Foulkes, W.D. Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer. Clin. Cancer Res. 2005, 11, 4003-4011.
90. Paredes, J.; Lopes, N.; Milanezi, F.; Schmitt, F. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch. 2007, 450, 73-80.
91. Potemski, P.; Kusinska, R.; Kubiak, R.; Piekarski, J.H.; Pluciennik, E.; Bednarek, A.K.; Kordek, R. Relationship of P-cadherin expression to basal phenotype of breast carcinoma. Polish J. Pathol. 2007, 58, 183-188.
92. Honeth, G.; Bendahl, P.-O.; Ringner, M.; Saal, L.; Gruvberger-Saal, S.; Lovgren, K.; Grabau, D.; Ferno, M.; Borg, A.; Hegardt, C. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. Treat. 2008, 10, R53.
93. Klingbeil, P.; Natrajan, R.; Everitt, G.; Vatcheva, R.; Marchio, C.; Palacios, J.; Buerger, H.; Reis-Filho, J.; Isacke, C. CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res. Treat. 2009, 120, 95-109.
94. Wienke, D.; Davies, G.C.; Johnson, D.A.; Sturge, J.; Lambros, M.B.K.; Savage, K.; Elsheikh, S.E.; Green, A.R.; Ellis, I.O.; Robertson, D.; et al. The Collagen Receptor Endo180 (CD280) Is Expressed on Basal-like Breast Tumor Cells and Promotes Tumor Growth In vivo. Cancer Res. 2007, 67, 10230-10240.
95. Garcia, S.; Dalès, J.-P.; Charafe-Jauffret, E.; Carpentier-Meunier, S.; Andrac-Meyer, L.; Jacquemier, J.; Andonian, C.; Lavaut, M.-N.; Allasia, C.; Bonnier, P.; et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Human Pathol. 2007, 38, 830-841.
96. Graveel, C.R.; DeGroot, J.D.; Su, Y.; Koeman, J.; Dykema, K.; Leung, S.; Snider, J.; Davies, S.R.; Swiatek, P.J.; Cottingham, S.; et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc. Natl. Acad. Sci. USA 2009, 106, 12909-12914.
97. Zabouo, G.; Imbert, A.-M.; Jacquemier, J.; Finetti, P.; Moreau, T.; Esterni, B.; Bertucci, F.; Chabannon, C. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res. 2009, 11, R1.
98. Ouhtit, A.; Gaur, R.L.; Abd Elmageed, Z.Y.; Fernando, A.; Thouta, R.; Trappey, A.K.; Abdraboh, M.E.; El-Sayyad, H.I.; Rao, P.; Raj, M.G.H. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim. Biophys. Acta 2009, 1795, 130-136.
99. Shih, L.M.; Hsu, M.Y.; Palazzo, J.P.; Herlyn, M. The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am. J. Pathol. 1997, 151, 745-751.
100. Arnes, J.B.; Begin, L.R.; Stefansson, I.; Brunet, J.S.; Nielsen, T.O.; Foulkes, W.D.; Akslen, L.A. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. J. Clin. Pathol. 2009, 62, 139-146.
101. Viale, G.; Rotmensz, N.; Maisonneuve, P.; Bottiglieri, L.; Montagna, E.; Luini, A.; Veronesi, P.; Intra, M.; Torrisi, R.; Cardillo, A.; et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res. Treat. 2009, 116, 317-328.
102. H. Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. Acta Pathol. Microbiol. Immunol. Scandinavica 2008, 116, 515-525.
103. Stratford, A.; Habibi, G.; Astanehe, A.; Jiang, H.; Hu, K.; Park, E.; Shadeo, A.; Buys, T.; Lam, W.; Pugh, T.; et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res. 2007, 9, R61.
104. Linderholm, B.K.; Hellborg, H.; Johansson, U.; Elmberger, G.; Skoog, L.; Lehtio, J.; Lewensohn, R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann. Oncol. 2009, 20, 1639-1646.
105. Ribeiro-Silva, A.; de Vale, F.R.; Zucoloto, S. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Am. J. Clin. Pathol. 2006, 125, 512-518.
106. Dent, S. F. The role of VEGF in triple-negative breast cancer: where do we go from here? Ann. Oncol. 2009, 20, 1615-1617.
107. Modjtahedi, H.; Essapen, S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anti-Cancer Drugs 2009, 20, 851-855.
108. Shahi, P.K.; Pineda, I.F. Tumoral Angiogenesis: Review of the Literature. Cancer Invest. 2008, 26, 104-108.
109. G. VEGF-Targeting Therapy for Breast Cancer. J. Mammary Gland Biol. Neoplasia 2005, 10, 319-323.
110. Tsuda, H.; Morita, D.; Kimura, M.; Shinto, E.; Ohtsuka, Y.; Matsubara, O.; Inazawa, J.; Tamaki, K.; Mochizuki, H.; Tamai, S.; et al. Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci. 2005, 96, 48-53.
111. Dickler, M.; Cobleigh, M.; Miller, K.; Klein, P.; Winer, E. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res. Treat. 2009, 115, 115-121.
112. Dickler, M.N.; Rugo, H.S.; Eberle, C.A.; Brogi, E.; Caravelli, J.F.; Panageas, K.S.; Boyd, J.; Yeh, B.; Lake, D.E.; Dang, C.T.; et al. A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer. Clin. Cancer Res. 2008, 14, 7878-7883.
113. Flynn, J.F.; Wong, C.; Wu, J.M. Anti-EGFR therapy: mechanism and advances in clinical efficacy in breast cancer. J. Oncol. 2009, 2009, 526963.
114. Modi, S.; D'Andrea, G.; Norton, L.; Yao, T.J.; Caravelli, J.; Rosen, P.; Hudis, C.; Seidman, A. A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer. Clin. Breast Cancer 2006, 7, 270-277.
115. Carey, L.A.; Rugo, H.S.; Marcom, P.K.; Irvin, W., Jr.; Ferraro, M.; Burrows, E.; He, X.; Perou, C.M.; Winer, E.P. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Presented at the 2008 ASCO Annual Meeting, Boston, MA, June 2008.
116. Conte, P.; Guarneri, V. Triple-negative breast cancer: current management and future options. Eur. J. Cancer Suppl. 2009, 7, 14-18.
117. Chia, K.; Tutt, A. Triple-negative breast cancer: an update. Adv. Breast Cancer 2007, 4, 75-80.
118. Saeki, R.; Kondoh, M.; Kakutani, H.; Tsunoda, S.-i.; Mochizuki, Y.; Hamakubo, T.; Tsutsumi, Y.; Horiguchi, Y.; Yagi, K. A Novel Tumor-Targeted Therapy Using a Claudin-4-Targeting Molecule. Mol. Pharmacol. 2009, 76, 918-926.
119. Rodriguez-Pinilla, S.M.; Sarrio, D.; Moreno-Bueno, G.; Rodriguez-Gil, Y.; Martinez, M.A.; Hernandez, L.; Hardisson, D.; Reis-Filho, J.S.; Palacios, J. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod. Pathol. 2007, 20, 474-481.
120. Ray, P.S.; Wang, J.; Qu, Y.; Shin-Sim, M.; Shamonki, J.; Liu, B.; Elashoff, D.; Hoon, D.S.; Giuliano, A.E.; Cui, X. Diagnostic and prognostic significance of FOXC1 expression in basal-like/triple-negative breast cancer. Poster presented at the ASCO 2009 Breast Cancer Symposium, San Francisco, CA, USA, October 2009.
121. Ray, P.S.; Wang, J.; Qu, Y.; Shin-Sim, M.; Shamonki, J.; Liu, B.; Hoon, D.S.; Giuliano, A.E.; Cui, X. Role of FOXC1 in regulation of basal-like/triple-negative breast cancer. Presented at the 2009 ASCO Annual Meeting, Orlando, FL, USA, May 2009.
122. Mani, S.A.; Yang, J.; Brooks, M.; Schwaninger, G.; Zhou, A.; Miura, N.; Kutok, J.L.; Hartwell, K.; Richardson, A.L.; Weinberg, R.A. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl. Acad. Sci. USA 2007, 104, 10069-10074.
123. Umemura, S.; Shirane, M.; Takekoshi, S.; Kusakabe, T.; Itoh, J.; Egashira, N.; Tokuda, Y.; Mori, K.; Osamura, Y.R. Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. Br. J. Cancer 2009, 100, 764-771.
124. Dahl, E.; En-Nia, A.; Wiesmann, F.; Krings, R.; Djudjaj, S.; Breuer, E.; Fuchs, T.; Wild, P.; Hartmann, A.; Dunn, S.; et al. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer 2009, 9, 410-426.
125. Janz, M.; Harbeck, N.; Dettmar, P.; Berger, U.; Schmidt, A.; Jürchott, K.; Schmitt, M.; Royer, H.-D. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int. J. Cancer 2002, 97, 278-282.
126. Wang, X.; Chao, L.; Li, X.; Ma, G.; Chen, L.; Zang, Y.; Zhou, G. Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and triple-negative breast cancers. Human Pathol. 2010, 41, 401-406.
127. Ribeiro-Silva, A.; Ramalho, L.N.Z.; Garcia, S.B.; Brandão, D.F.; Chahud, F.; Zucoloto, S. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 2005, 47, 458-466.
128. Chae, B.J.; Bae, J.S.; Lee, A.; Park, W.C.; Seo, Y.J.; Song, B.J.; Kim, J.S.; Jung, S.S. p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer. Jpn. J. Clin. Oncol. 2009, 39, 217-224.
129. Manie, E.; Vincent-Salomon, A.; Lehmann-Che, J.; Pierron, G.; Turpin, E.; Warcoin, M.; Gruel, N.; Lebigot, I.; Sastre-Garau, X.; Lidereau, R.; et al. High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors. Cancer Res. 2009, 69, 663-671.
130. Foulkes, W.D.; Brunet, J.-S.; Stefansson, I. M.; Straume, O.; Chappuis, P.O.; Begin, L.R.; Hamel, N.; Goffin, J.R.; Wong, N.; Trudel, M.; et al. The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer. Cancer Res. 2004, 64, 830-835.
131. Rakha, E.A.; Putti, T.C.; El-Rehim, D.M.A.; Paish, C.; Green, A.R.; Powe, D.G.; Lee, A.H.; Robertson, J.F.; Ellis, I.O. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 2006, 208, 495-506.
132. Yehiely, F.; Moyano, J.V.; Evans, J.R.; Nielsen, T.O.; Cryns, V.L. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol. Med. 2006, 12, 537-544.
133. Bolshakov, S.; Walker, C.M.; Strom, S.S.; Selvan, M.S.; Clayman, G.L.; El-Naggar, A.; Lippman, S.M.; Kripke, M.L.; Ananthaswamy, H.N. p53 Mutations in Human Aggressive and Nonaggressive Basal and Squamous Cell Carcinomas. Clin. Cancer Res. 2003, 9, 228-234.
134. T. p53 alterations in human cancer: more questions than answers. Oncogene 2007, 26, 2145-2156.
135. Alsner, J.; Jensen, V.; Kyndi, M.; Vrou Offersen, B.; Vu, P.; Borresen-Dale, A.-L.; Overgaard, J. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol. 2008, 47, 600-607.
136. Chappuis, P.O.; Donato, E.; Goffin, J.R.; Wong, N.; Begin, L.R.; Kapusta, L.R.; Brunet, J.S.; Porter, P.; Foulkes, W.D. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann. Oncol. 2005, 16, 735-742.
137. Signoretti, S.; Di Marcotullio, L.; Richardson, A.; Ramaswamy, S.; Isaac, B.; Rue, M.; Monti, F.; Loda, M.; Pagano, M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 2002, 110, 633-641.
138. Voduc, D.; Nielsen, T.O.; Cheang, M.C.; Foulkes, W.D. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Human Pathol. 2008, 39, 1431-1437.
139. Gauthier, M.L.; Berman, H.K.; Miller, C.; Kozakeiwicz, K.; Chew, K.; Moore, D.; Rabban, J.; Chen, Y.Y.; Kerlikowske, K.; Tlsty, T.D. Abrogated Response to Cellular Stress Identifies DCIS Associated with Subsequent Tumor Events and Defines Basal-like Breast Tumors. Cancer Cell 2007, 12, 479-491.
140. Herschkowitz, J.; He, X.; Fan, C.; Perou, C. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res. 2008, 10, R75.
141. Subhawong, A.P.; Subhawong, T.; Nassar, H.; Kouprina, N.; Begum, S.; Vang, R.; Westra, W.H.; Argani, P. Most Basal-like Breast Carcinomas Demonstrate the Same Rb-/p16+ Immunophenotype as the HPV-related Poorly Differentiated Squamous Cell Carcinomas Which They Resemble Morphologically. Am. J. Surg. Pathol. 2009, 33, 163-175.
142. Yerushalmi, R.; Woods, R.; Ravdin, P.M.; Hayes, M.M.; Gelmon, K.A. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010, 11, 174-183.
143. Livasy, C.A.; Perou, C.M.; Karaca, G.; Cowan, D.W.; Maia, D.; Jackson, S.; Tse, C.-K.; Nyante, S.; Millikan, R.C. Identification of a basal-like subtype of breast ductal carcinoma in situ. Human Pathol. 2007, 38, 197-204.
144. Wirapati, P.; Sotiriou, C.; Kunkel, S.; Farmer, P.; Pradervand, S.; Haibe-Kains, B.; Desmedt, C.; Ignatiadis, M.; Sengstag, T.; Schutz, F.; et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10, R65.
145. Desmedt, C.; Haibe-Kains, B.; Wirapati, P.; Buyse, M.; Larsimont, D.; Bontempi, G.; Delorenzi, M.; Piccart, M.; Sotiriou, C. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. Clinical Cancer Res. 2008, 14, 5158-5165.
146. Ashworth, A. A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair. J. Clin. Oncol. 2008, 26, 3785-3790.
147. Foulkes, W.D.; Stefansson, I.M.; Chappuis, P.O.; Begin, L.R.; Goffin, J.R.; Wong, N.; Trudel, M.; Akslen, L.A. Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer. J. Natl. Cancer Inst. 2003, 95, 1482-1485.
148. Silver, D.P.; Richardson, A.L.; Eklund, A.C.; Wang, Z.C.; Szallasi, Z.; Li, Q.; Juul, N.; Leong, C.-O.; Calogrias, D.; Buraimoh, A.; et al. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. J. Clin. Oncol. 2010, 28, 1145-1153.
149. Turner, N.C.; Reis-Filho, J.S.; Russell, A.M.; Springall, R.J.; Ryder, K.; Steele, D.; Savage, K.; Gillett, C.E.; Schmitt, F.C.; Ashworth, A.; et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2006, 26, 2126-2132.
150. Gilbert, P.M.; Mouw, J.K.; Unger, M.A.; Lakins, J.N.; Gbegnon, M.K.; Clemmer, V.B.; Benezra, M.; Licht, J.D.; Boudreau, N.J.; Tsai, K.K.C.; et al. HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J. Clin. Invest. 2010, 120, 1535-1550.
151. Lacroix, M.; Leclercq, G. The "portrait" of hereditary breast cancer. Breast Cancer Res. Treat. 2005, 89, 297-304.
152. Lakhani, S.R.; O'Hare, M.J.; Ashworth, A. Profiling familial breast cancer. Nat. Med. 2001, 7, 408-410.
153. Hosey, A.M.; Gorski, J.J.; Murray, M.; Quinn, J.E.; Chung, W.Y.; Stewart, G.E.; James, C.R.; Farragher, S.M.; Mulligan, J.M.; Scott, A.N.; et al. Molecular Basis for Estrogen Receptor {alpha} Deficiency in BRCA1-Linked Breast Cancer. J. Natl. Cancer Inst. 2007, 99, 1683-1694.
154. Gorski, J.; James, C.; Quinn, J.; Stewart, G.; Staunton, K.; Buckley, N.; McDyer, F.; Kennedy, R.; Wilson, R.; Mullan, P.; et al. BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res. Treat. 2009, doi:10.1007/s10549-009-0565-0.
155. Liu, X.; Holstege, H.; van der Gulden, H.; Treur-Mulder, M.; Zevenhoven, J.; Velds, A.; Kerkhoven, R.M.; van Vliet, M.H.; Wessels, L.F.A.; Peterse, J.L.; et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 12111-12116.
156. McCarthy, A.; Savage, K.; Gabriel, A.; Naceur, C.; Reis-Filho, J.S.; Ashworth, A. A mouse model of basal-like breast carcinoma with metaplastic elements. J. Pathol. 2007, 211, 389-398.
157. Tan, A.R.; Swain, S.M. Therapeutic Strategies for Triple-Negative Breast Cancer. Cancer J. 2008, 14, 343-351.
158. Ashworth, A. A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair. J. Clin. Oncol. 2008, 26, 3785-3790.
159. Stebbing, J.; Ellis, P.; Tutt, A. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. Future Oncol. 2010, 6, 485-486.
160. Fong, P.C.; Boss, D.S.; Carden, C.P.; Roelvink, M.; De Greve, J.; Gourley, C.M.; Carmichael, J.; De Bono, J.S.; Schellens, J.H.M.; Kaye, S.B. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. Presented at the 2008 ASCO Annual Meeting, Boston, MA, USA, June 2008.
161. Yap, T.A.; Boss, D.S.; Fong, P.C.; Roelvink, M.; Tutt, A.; Carmichael, J.; O'connor, M.J.; Kaye, S.B.; Schellens, J.H.M.; de Bono, J.S. First in human phase I pharmacokinetic and pharmacodynamic study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients, including BRCA1/2 mutation carriers. Presented at the 2007 ASCO Annual Meeting, Chicago, IL, USA, June 2007.
162. Walter, O.; Prasad, M.; Lu, S.; Quinlan, R.M.; Edmiston, K.L.; Khan, A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Human Pathol. 2009, 40, 1528-1533.
163. Nalwoga, H.; Arnes, J.B.; Wabinga, H.; Akslen, L.A. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br. J. Cancer 2010, 102, 369-375.
164. Resetkova, E.; Reis-Filho, J.; Jain, R.; Mehta, R.; Thorat, M.; Nakshatri, H.; Badve, S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res. Treat. 2009, doi: 10.1007/s10549-009-0619-3.
165. Otterbach, F.; Callies, R.; Adamzik, M.; Kimmig, R.; Siffert, W.; Schmid, K.; Bankfalvi, A. Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas. Breast Cancer Res. Treat. 2009, 120, 67-76.
166. Arai, K.; Takano, S.; Teratani, T.; Ito, Y.; Yamada, T.; Nozawa, R. S100A8 and S100A9 Overexpression Is Associated with Poor Pathological Parameters in Invasive Ductal Carcinoma of the Breast. Curr. Cancer Drug Targets 2008, 8, 243-252.
167. Arai, K.; Teratani, T.; Kuruto-Niwa, R.; Yamada, T.; Nozawa, R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur. J. Cancer 2004, 40, 1179-1187.
168. Skaland, I.; Janssen, E.A.M.; Gudlaugsson, E.; Hui Ru Guo, L.; Baak, J.P.A. The prognostic value of the proliferation marker Phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer. Cell. Oncol. 2009, 31, 261-271.
169. Kuroda, H.; Ishida, F.; Nakai, M.; Ohnisi, K.; Itoyama, S. Basal cytokeratin expression in relation to biological factors in breast cancer. Human Pathol. 2008, 39, 1744-1750.
170. Lancashire, L.; Powe, D.; Reis-Filho, J.; Rakha, E.; Lemetre, C.; Weigelt, B.; Abdel-Fatah, T.; Green, A.; Mukta, R.; Blamey, R.; et al. A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res. Treat. 2009, 120, 83-93.
171. Tang, X.Y.; Umemura, S.; Tsukamoto, H.; Kumaki, N.; Tokuda, Y.; Osamura, R.Y. Overexpression of fatty acid binding protein-7 correlates with basal-like subtype of breast cancer. Pathol. Res. Prac. 2010, 206, 98-101.
172. Moyano, J.V.; Evans, J.R.; Chen, F.; Lu, M.; Werner, M.E.; Yehiely, F.; Diaz, L.K.; Turbin, D.; Karaca, G.; Wiley, E.; et al. alphaB-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest. 2006, 116, 261-270.
173. Sitterding, S.M.; Wiseman, W.R.; Schiller, C.L.; Luan, C.; Chen, F.; Moyano, J.V.; Watkin, W.G.; Wiley, E.L.; Cryns, V.L.; Diaz, L.K. alphaB-crystallin: A novel marker of invasive basal-like and metaplastic breast carcinomas. Ann. Diagn. Pathol. 2008, 12, 33-40.
174. Pal, S.; Childs, B.; Pegram, M. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. Breast Cancer Res. Treat. 2010, 119, 25-32.
175. Choi, W.W.L.; Weisenburger, D.D.; Greiner, T.C.; Piris, M.A.; Banham, A.H.; Delabie, J.; Braziel, R.M.; Geng, H.; Iqbal, J.; Lenz, G.; et al. A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. Clin. Cancer Res. 2009, 15, 5494-5502.
176. Geiss, G.K.; Bumgarner, R.E.; Birditt, B.; Dahl, T.; Dowidar, N.; Dunaway, D.L.; Fell, H.P.; Ferree, S.; George, R.D.; Grogan, T.; et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotech. 2008, 26, 317-325.
177. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F.L.; Walker, M.G.; Watson, D.; Park, T.; et al. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. N. Engl. J. Med. 2004, 351, 2817-2826.
178. Rimsza, L.M.; LeBlanc, M.L.; Unger, J.M.; Miller, T.P.; Grogan, T.M.; Persky, D.O.; Martel, R.R.; Sabalos, C.M.; Seligmann, B.; Braziel, R.M.; et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008, 112, 3425-3433.
179. Sotiriou, C.; Pusztai, L. Gene-Expression Signatures in Breast Cancer. N. Engl. J. Med. 2009, 360, 790-800.
180. Schneider, B.P.; Winer, E.P.; Foulkes, W.D.; Garber, J.; Perou, C.M.; Richardson, A.; Sledge, G.W.; Carey, L.A. Triple-Negative Breast Cancer: Risk Factors to Potential Targets. Clin. Cancer Res. 2008, 14, 8010-8018.